NEWS FLASH

SOSV joins Sundew Seed Financing

Completes round led by Yield Lab in November
SOSV's Bill Liao becomes Sundew board observer

17 March 2022. Sundew, an advanced biology venture targeting aquatic pests, diseases and invasive species, announces that SOSV has joined Sundew's seed financing round. The Yield Lab Europe and The Danish Growth Fund participated in November 2021. In connection to their investment, Bill Liao of SOSV will become a board observer of Sundew. The investment sum is undisclosed.

Giovanni Salerno, Sundew's CEO, said, '*we are delighted to add SOSV to our investor roster and board. Their deep and broad industry and investor contacts will help Sundew to further accelerate our portfolio of effective, affordable and environmentally benign biological products, delivering innovative solutions that meet major needs in key aquatic markets'.*

Bill Liao, Partner at SOSV said, *"SOSV is delighted to invest in this world-changing technology company that is set to revolutionize the care of major commercial aquaculture species. SOSV has an ongoing commitment to planetary health and the Sundew platform is well aligned."*

About Sundew

Sundew ApS is a Danish-Dutch venture focused on combating aquatic pests, diseases and invasive species using advanced biological approaches. Modern biology offers the capability to provide effective, affordable and environmentally benign solutions to the multiple pest, disease and ecological problems afflicting the world's oceans, seas, lakes and rivers.

Sundew is building a portfolio of products based on two technology platforms:

- **Natural ingredients and aquatic beneficial organisms**. Sundew's most advanced product from this platform works against multiple protozoan parasites. One of the most important is Ich, a parasitic disease caused by the protozoan *Ichthyophthirius multifiliis* (and otherwise known as fish white spot disease). It is a major disease of freshwater fish, including such species as koi, rainbow trout, young salmon, catfish and carp.
- **Algal RNA technologies**. This will both protect aquaculture species against disease, and target aquatic invasive species. RNA is becoming increasingly important as a treatment in the human therapeutic and vaccine space but requires specific delivery mechanisms for use in aquatic environments. Since algae are a major component of many aquatic species' diets, they have many advantages when use in this way.

Both platforms use fermentation as their production technology. More info at www.sundew.bio

About SOSV

SOSV.com is a billion-dollar global investment fund with offices around the world.

Contact

Giovanni Salerno, CEO giovannis@sundew.bio +45 28 717 717